Share/Bookmark

JM SpecialistsPatients Urgently Needed for Drug Trial

Help us advance Juvenile Myositis research by volunteering for this drug trial!

AID Clinical Trial: Abatacept In Juvenile Dermatomyositis

The Myositis center at The George Washington University is conducting a clinical trial entitled "Abatacept for the Treatment of Refractory Juvenile Dermatomyositis". As you know this biologic agent is FDA-approved for use in rheumatoid arthritis and there is evidence that targeting CTLA-4 in myositis may be beneficial. This is an open label trial to assess the safety and efficacy of subcutaneous abatacept in 10 patients with refractory JDM. The study entails 5 protocol visits over the course of six months. Patients will receive weekly subcutaneous Abatacept for the duration of the study ( 6 month extension is available for those patients with a positive response). Study drug is supplied at no cost to the patient and travel support is available for all patients after the screening visit.
 
The inclusion criteria include:

  1. Definite or probable  juvenile dermatomyositis  by Bohan and Peter criteria.
  2. Age 7 years or older.
  3. Body weight 25kg (55lbs) or more.
  4. Moderately active dermatomyositis confirmed by our investigators on the screening visit based on the core set myositis measures in our study criteria.
  5. The patient must be on a stable dose of prednisone (4 weeks) and /or other immunosuppressive medication (6 weeks) prior to visit 1, and failed prednisone and 1 other immunosuppressive medication.

CLICK HERE FOR MORE INFORMATION ABOUT THIS TRIAL AND ELIGIBILITY CRITERIA

You can also contact Hassan Awal at hawal@mfa.gwu.edu or call (202) 741-2389

VIEW/PRINT A FLYER